ClinicalTrials.gg

Program

fitusiran

Also written as “Fitusiran”, “Fitusiran (SAR439774)” and “ALN-AT3SC”.

Its studies are mostly in Hemophilia A, led by Sanofi.

Furthest: phase 4, since Nov 17, 202310 company-led studies, 3 open or runningNext primary completion: Mar 25, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi103 open or runningphase 4since Nov 17, 2023Jan 13, 2014Mar 25, 2027phase 3 · NCT05662319

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 13, 2014First study: phase 1 study in Hemophilia AFirst studyNCT02035605 · 51 enrolled · United States, Bulgaria, Russian Federation and more
  2. Sep 15, 2015Phase 2 study in Hemophilia ANCT02554773 · 34 enrolled · United States, Bulgaria, Russian Federation and more
  3. Jan 25, 20182 phase 3 studies in Hemophilia ANCT03417245, NCT03417102
  4. May 25, 2018Phase 3 study in Hemophilia ANCT03549871 · 80 enrolled · United States, Australia, China and more
  5. Nov 25, 2018Phase 3 study in Hemophilia ANCT03754790 · 281 enrolled · United States, Australia, Canada and more
  6. Jun 3, 2019Phase 3 study in Hemophilia ANCT03974113 · 32 enrolled · United States, Canada, India and more
  7. Dec 14, 2022Phase 3 study in Hemophilia ANCT05662319 · 91 enrolled · United States, Canada, China and more
  8. Nov 17, 2023Phase 4 study in Hemophilia ANCT06145373 · 20 planned · United States, Taiwan
  9. Dec 9, 2025Phase 3 study in Hemophilia ANCT07285460 · 85 planned · United States, Belgium, Brazil and more

Ahead

  1. Mar 25, 2027Primary completion: phase 3 study in Hemophilia ANCT05662319
  2. May 28, 2028Primary completion: phase 4 study in Hemophilia ANCT06145373
  3. Aug 4, 2029Primary completion: phase 3 study in Hemophilia ANCT07285460

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07285460Hemophilia A · United States, Belgium, Brazil and more3RecruitingAug 4, 202985
NCT06145373Hemophilia A · United States, Taiwan4RecruitingMay 28, 202820
NCT05662319Hemophilia A · United States, Canada, China and more3Active, not recruitingMar 25, 202791
NCT03974113Hemophilia A · United States, Canada, India and more3CompletedAug 4, 202632
NCT03754790Hemophilia A · United States, Australia, Canada and more3CompletedSep 14, 2026281
NCT03549871Hemophilia A · United States, Australia, China and more3CompletedJan 20, 202280
NCT03417245Hemophilia A · United States, Australia, China and more3CompletedJan 26, 2021120
NCT03417102Hemophilia A · United States, Australia, Canada and more3CompletedNov 25, 202060
NCT02554773Hemophilia A · United States, Bulgaria, Russian Federation and more2CompletedMar 21, 202334
NCT02035605Hemophilia A · United States, Bulgaria, Russian Federation and more1CompletedJul 20, 201751

How it is read

Names in the registry

  • “Fitusiran”, 5 entries
  • “Fitusiran (SAR439774)”, 2 entries
  • “fitusiran”, 2 entries
  • “ALN-AT3SC”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.